OPPORTUNITIES TO DIAGNOSE ACTIVE TUBERCULOSIS IN THE PATIENTS WITH CLINICALLY CURED RESPIRATORY TUBERCULOSIS
https://doi.org/10.21292/2075-1230-2017-95-4-37-44
Abstract
Goal of the study: to evaluate the test with tuberculous recombinant allergen (TRA) in the patients with effective treatment course due to tuberculosis, to investigate the impact of clinical, epidemiological and social factors on persistence of active tuberculosis.
Materials and methods. Patients were divided into 2 groups basing on time period after completion of the main treatment course. Group I – 32 patients (up to 6 months), group II – 63 patients (more than 6 months).
Results of the study. Results of TRA tests in Group I remained positive in 34.4% of patients and in Group II - 23.8%. The average size of the induration in Group I made 10 mm(95% CI 6.5-13.3), in Group II – 13 mm (95% CI 8.4-19.7) Patients from Group I had positive results of TRA test more often in case of initial infiltrate form of pulmonary tuberculosis and bacillary excretion. In patients from Group II the positive TRA results correlated with presence of concurrent conditions and exposure to a tuberculosis case in the past. Positive results were confidently more often observed in lonely patients in both groups. TRA test can be a valuable tool to evaluate the risk of tuberculosis relapse after completion of the main treatment course.
About the Authors
G. S. Balasanyants
S. M. Kirov Military Medical Academy
Russian Federation
Russian Federation
N. S. Skotnikova
TB Dispensary no. 5
Russian Federation
Russian Federation
References
1. Аksenova V.А., Baryshnikova L.А., Klevno N.I. et al. Novye vozmozhnosti skrininga i diagnostiki razlichnykh proyavleniy tuberkuleznoy infektsii u detey i podrostkov v Rossii. [New opportunities for screening and diagnostics of various manifestations of tuberculous infection in children and adolescents in Russia]. In: Kozhnaya proba s preparatom Diaskintest - novye vozmozhnosti identifikatsii tuberkuleznoy infektsii. [Skin test with the use of Diaskintest – new opportunities for tuberculous infection identification]. Part 2, ch. 1, 2nd ed.,revised and suppl., ed. by M.A. Paltsev, Moscow, Shiko Publ., 2011, pp. 134-152. (In Russ.)
2. Аksenova V.А., Moiseeva N.N., Klevno N.I., Odinets V.S., Baronova O.D. Efficiency of various screening methods of early detection of tuberculosis in children and adolescents. Vopr. Praktich. Pediatrii, 2016, vol. 11, no. 4, pp. 9-17. (In Russ.)
3. Barmina N.А., Baryshnikova L.А., Shurygin А.А., Reykhardt V.V. Screening in children and adolescents of III, IV and V health groups with the use of a new diagnostic test. Tuberculosis and Lung Diseases, 2015, no. 5, pp. 40-41. (In Russ.)
4. Vasilieva I.A. Tuberculosis control strategy in Russia till 2020. Doklad na X s"ezde ftiziatrov Rossiyskoy Federatsii. [Presentation at the Xth Conference of Russian TB Doctors]. 26.05.2015. [Epub.]
5. Vilderman A.M. Course of the disease and outcomes of concurrent conditions – active tuberculosis and non-specific pulmonary tuberculosis. Probl. Tub., 1987, no. 3, pp. 19-22. (In Russ.)
6. Zorina M.M. Latentnaya tuberkuleznaya infektsiya u sotrudnikov protivotuberkuleznykh organizatsiy: diagnostika, faktory riska, profilaktika kand. med. nauk. [Latent tuberculous infection in the workers of TB units: diagnostics, risk factors, prevention. Cand. Diss.]. Novosibirsk, 2015, 26 p.
7. Ivanova Z.А., Glebova V.Yu., Pasechnik А.V., Аbdulkhaev V.V., Аrsentieva N.V. Concurrent conditions of tuberculosis as a cause complicating the course and treatment of tuberculosis. Uspekhi Sovremen. Estestvoznaniya, 2011, no. 4, pp. 124-125. (In Russ.)
8. Kiselev V.I., Baranovskiy P.M., Pupyshev S.А., Rudykhin I.V., Perelman M.I., Paltseva M.А. New skin test for tuberculosis diagnostics based on recombinant protein of ESAT-CFP. Molekulyar. Meditsina, 2008, no. 4, pp. 28-35. (In Russ.)
9. Kozhnaya proba s preparatom Diaskintest – novye vozmozhnosti identifikatsii tuberkuleznoy infektsii. [Skin test with the use of Diaskintest - new opportunities for tuberculous infection identification]. Edited by M.A. Paltsev, 5nd ed., suppl. and amend., Moscow, Shiko Publ., 2011.
10. Litvinov V.I. Latent tuberculous infection – myth or reality? Tuberculosis and Lung Diseases, 2011, no. 6, pp. 3-9. (In Russ.)
11. Litvinov V.I., Slogotskaya L.V. DIASKINTEST – a new diagnostic tool for tuberculosis diagnosis. Physiology and pathology of the immune system. Immunofarmakogenomika, 2011, vol. 15, no. 2, pp. 11-21. (In Russ.)
12. Parfenova T.A. Experience of using recombinant allergen of Mycobacterium tuberculosis for diagnostics of tuberculous infection Tuberculosis and Lung Diseases, 2016, vol. 94, no. 9, pp. 49-52. (In Russ.)
13. Poddubnaya L.V., Chikurova T.N., Fedorova M.V., Igonina O.V., Dorogan V.А., Zyryanova T.V. Sensitivity of the skin test with tuberculous allergen in TB/HIV patients. Tuberculosis and Lung Diseases, 2015, no. 4, pp. 16-20. (In Russ.)
14. Edict no. 109 by RF MoH as of 21.03.2003 On Improvement of TB Control Measures in the Russian Federation, Annex no. 12 On Recommendations on anti-epidemic measures in the tuberculosis foci. (In Russ.)
15. Edict no. 855 as of 29.10.2009 by the Russian Ministry of Health and Social Development On Changes to Appendix no. 4 to Edict no. 109 as of 21.03.2003 by the Russian Ministry of Health. (In Russ.)
16. Edict no. 951 by RF MoH as of 29.12.2014 On Approval of Guidelines for Improvement of Respiratory Tuberculosis Diagnostics and Treatment. (In Russ.)
17. Senin А.M., Eysmont N.V., Golubev D.N. Use of Diaskintest for the evaluation of activity of tuberculous infection among the patients of anti-tuberculosis service with concurrent HIV infection. Vestn. Sovr. Klin. Med., 2016, vol. 9, iss., 4. pp. 101-107. (In Russ.)
18. Slogotskaya L.V. Effektivnost kozhnogo testa s allergenom tuberkuleznym, soderzhaschim rekombinantniy belok ESAT6 CFP10 v diagnostike, vyavlenii i opredelnii aktivnosti tuberkuleznoy infektsii. Avtoref. diss. dokt. med. nauk. [Efficiency of skin test with tuberculous allergen containing recombinant protein of ESAT6 CFP10 for diagnostics, detection and defining of the tuberculous infection activity. Doct. Diss.]. Moscow, 2011, 45 p.
19. Slogotskaya L.V., Kochetkov Ya.А., Senchikhina O.Yu. et al. Changes in skin test (diaskintest) in children when assessing the activity of tuberculosis infection. Tuberculosis and Lung Diseases, 2011, no. 2, pp. 59-63. (In Russ.)
20. Slogotskaya L.V., Ovsyankina E.S., Kochetkov Ya.А., Stakheeva L.B. The incidence of tuberculous infection in children and adolescents – view over the century. Tuberculosis and Lung Diseases, 2010, no. 6, pp. 21-28. (In Russ.)
21. Slogotskaya L.V., Filippov А.V., Kochetkov Ya.А., Seltsovskiy P.P., Litvinov V.I.Sensitivity and specificity of Diaskintest in those suffering from tuberculosis and other non-tuberculous pulmonary diseases. Ross. Med. Journal, 2011, no. 4, pp. 15-19. (In Russ.)
22. Tyulkova T.E., Kornachev A.C., Chugaev Yu.P., Kashuba E.А., Kulikova I.B., Beloborodova N.G., Аndreeva L.V., Kozlova А.V., Kashuba E.V., Khmeleva E.F., Molokova O.M. Criteria for prognosis of development of latent tuberculosis into clinically active form. Probl. Tuberkuleza i Bolezni Legkikh, 2008, no. 7, pp. 29-35. (In Russ.)
23. Al-Darraji H.A., Kamarulzaman A., Altice F.L. Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health, 2014, vol. 14, no. 1, pp. 22.
24. Amita Jain, Pratima Dixit, Rajendra Prasad. Pre-XDR & XDR in MDR and Ofloxacin and Kanamycin resistance in non-MDR Mycobacterium tuberculosis isolates. Tuberculosis, 2012, vol. 92, issue 5, pp. 404-406.
25. Andersen P., Andersen A., Sorensen A. et al. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Immunol., 1995, vol. 154, no. 7, pp. 3359-3372.
26. Baker M.A., Harries A.D., Jeon C.Y., Hart J.E., Kapur A., Lönnroth K., Ottmani S.-E., Goonesekera S.D., Murray M.B. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med., 2011, vol. 9, pp. 81.
27. Bakir M., Millington K., Soysal A. et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann. Intern. Med., 2008, vol. 149, no. 11, pp. 777-787
28. Bloss E., Kuksa L., Holtz T.H., Riekstina V., Skripconoka V., Kammerer S., Leimane V. Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004. Int. J. Tuberc. Lung Dis., 2010, vol. 14, no. 3, pp. 275-281.
29. Chee C.B., Sester M., Zhang W., Lange C. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology, 2013, vol. 18, no. 2, pp. 205-216.
30. Cliff J.M., Cho J.E., Lee J.S., Ronacher K., King E.C., van Helden P., Walzl G., Dockrell H.M. Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment. J. Infect. Dis., 2015, vol. 7. pii: jiv447. [Epub ahead of print]
31. D’Ambrosio L., Dara M., Tadolini M. et al. TB elimination: theory and practice in Europe. Eur. Respir. J., 2014, vol. 43, pp. 1410-1420.
32. Dheda K., Gumbo T., Gandhi N. R., Murray M., Theron G., Udwadia Z., Migliori G.B., Warren R. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir. Med., 2014, vol. 2, pp. 321-338.
33. Diel R., Goletti D., Ferrara G., Bothamley G., Cirillo D., Kampmann B., Lange C., Losi M., Markova R., Migliori G.B., Nienhaus A., Ruhwald M., Wagner D., Zellweger P.J., Huitric E., Sandgren A., Manissero D. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur. Respir. J., 2011, vol. 37, no. 1, pp. 88-99.
34. Diel R., Loddenkemper R., Zellweger J.P. et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur. Respir. J., 2013, vol. 42, pp. 785-801.
35. Dietrich J., Aagaard C., Leah R. et al. Exchanging ESAT6 with TB 10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol., 2005, vol. 174, pp. 6332-6339.
36. Dorman S.E., Belknap R., Graviss E.A. et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am. J. Respir. Crit. Care Med., 2014, vol. 189, pp. 77-87.
37. Global Tuberculosis Report 2016. WHO/HTM/TB/2016.13. Geneva, World Health Organization, 2016.
38. Kempker R.R., Kipiani M., Mirtskhulava V., Tukvadze N., Magee M.J., Blumberg H.M. Acquired drug resistance in Mycobacterium tuberculosis and poor outcomes among patients with multidrug-resistant tuberculosis. Emerg. Infect. Dis., 2015, vol. 21, no. 6, pp. 992-1001.
39. Kim L., Moonan P.K., Heilig C.M. et al. Factors associated with recurrent tuberculosis more than 12 months after treatment completion. Int. J. Tuberc. Lung Dis., 2016, vol. 20, no. 1, pp. 49-56(8).
40. Lienhardt C., Fielding K., Hane A. et al. Evaluation of the prognostic value of IFN-γ release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in Senegal. PLoS One, 2010, vol. 5, no. 5, pp. 10508.
41. Lin P.L., Flynn J.L. Understanding latent tuberculosis: a moving target. J. Immunology, 2010, vol. 185, no. 1, pp. 15-22.
42. Lönnroth K., Williams B.G., Jaramillo E. et al. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health, 2008, vol. 8, pp. 289.
43. Mazurek G.H., Zajdowicz M.J., Hankinson A.L., Costigan D.J., Toney S.R., Rothel J.S. et al. Detection of Mycobacterium tuberculosis infection in United States Navy recruits using the tuberculin skin test or whole-blood interferongamma release assays. Clin. Infect. Dis., 2007, vol. 45, no. 7, pp. 826-836.
44. Menzies T., Pai M., Сomstock G. Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research march. Annals. Intern. Med., 2007, vol. 146, pp. 340-354.
45. Miyata T., Cheigh C.I., Casali N., Goodridge A., Marjanovic O., Kendall L.V., Riley L.W. An adjunctive therapeutic vaccine against reactivation and post-treatment relapse tuberculosis. Vaccine, 2012, vol. 30, no. 2, pp. 459-465.
46. Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: an interferon-y-based assay using new antigens. Am. J. Respir. Crit. Care Med., 2004, vol. 170, pp. 59-64.
47. Munk M., Arend S., Brock I. et al. Use of ESAT-6 and CFP-10 antigens for diagnosis of extrapulmonary tuberculosis. J. Infect. Dis., 2001, vol. 183, no. 1, pp. 175-176.
48. Pinto L.M., Grenier J., Schumacher S.G., Denkinger C.M., Steingart K.R., Pai M. Immunodiagnosis of tuberculosis: State of the Art. Med. Princ. Pract., 2012, no. 21, pp. 4-13.
49. Shih T.Y., Ho S.C., Hsiong C.H., Huang T.Y., Hu O.Y. Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity. Curr. Drug. Metab., 2013, vol. 14, no. 6, pp. 720-728.
50. Vordermeier H., Chambers M., Cockle P. et al. Correlation of ESAT-6- specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis. Infect. Immun., 2002, vol. 70, pp. 3026-3032.
51. World Health Organization (2011) Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries. Policy Statement, pp. 1-61.
52. Wu S., Zhang Y., Sun F., Chen M., Zhou L., Wang N., Zhan S. Adverse events associated with the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis. Am. J. Ther., 2013, Nov 26. [Epub ahead of print]
Review
For citations:
Balasanyants G.S., Skotnikova N.S. OPPORTUNITIES TO DIAGNOSE ACTIVE TUBERCULOSIS IN THE PATIENTS WITH CLINICALLY CURED RESPIRATORY TUBERCULOSIS. Tuberculosis and Lung Diseases. 2017;95(4):37-44. (In Russ.) https://doi.org/10.21292/2075-1230-2017-95-4-37-44
Views:
1046
Email this article 